Alunbrig (brigatinib) 180 mg, 28 film-coated tablets, Penn Pharmaceutical, United Kingdom, original Alunbrig (brigatinib) is used for certain ALK-positive non-small cell lung cancers. Medicine delivery from Europe within 4-5 days with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.
Delivery methods
- We can ship by mail to any European country with a delivery time of 8-10 days. Only medications that do not require refrigeration possible shipping. Shipping costs are 40-50 euro, depending on the destination country.
Delivery time
- Originator medicines: 8-10 days
- Generic medicines: 8-10 days
Payment methods
- Bank transfer to the settlement account after receiving the order
Indications
Alunbrig as monotherapy is indicated for the treatment adult patients with anaplastic lymphoma kinase (ALK)-positive advanced NSCLC who have not previously received treatment with an ALK inhibitor.
Alunbrig as monotherapy is indicated for the treatment of adult patients with advanced ALK-positive NSCLC who have previously received crizotinib.
Dose
A single dose of Alunbrigu is recommended® is 90 mg once daily for the first 7 days followed by a dose of 180 mg once daily.
Yaksto zastosuvannya Alunbrigu® Interrupted for 14 days or more for reasons other than adverse reactions, treatment should be resumed at a dose of 90 mg once daily for 7 days before increasing to a previously well-tolerated dose.
- Trade name:Alunbrig
- Chemical name:Brigatinib
- Dosage:180 mg
- Quantity:28
- Dosage form:Tablets
- Manufacturer:Penn Pharmaceutical, United Kingdom
No reviews yet
